WO1980002641A1 - Blood vessel prosthesis - Google Patents

Blood vessel prosthesis Download PDF

Info

Publication number
WO1980002641A1
WO1980002641A1 PCT/SE1980/000161 SE8000161W WO8002641A1 WO 1980002641 A1 WO1980002641 A1 WO 1980002641A1 SE 8000161 W SE8000161 W SE 8000161W WO 8002641 A1 WO8002641 A1 WO 8002641A1
Authority
WO
WIPO (PCT)
Prior art keywords
blood vessel
vessel prosthesis
resorbable
tubular element
prosthesis according
Prior art date
Application number
PCT/SE1980/000161
Other languages
French (fr)
Inventor
S Bowald
C Busch
I Eriksson
Original Assignee
S Bowald
C Busch
I Eriksson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by S Bowald, C Busch, I Eriksson filed Critical S Bowald
Priority to DE803047573T priority Critical patent/DE3047573T1/en
Priority to AU59897/80A priority patent/AU539875B2/en
Publication of WO1980002641A1 publication Critical patent/WO1980002641A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14Macromolecular materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/04Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
    • A61F2/06Blood vessels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2210/00Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2210/0004Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof bioabsorbable

Definitions

  • the present invention relates to a new type of blood vessel prosthesis for permanent or long-term implantation, which has clearly improved properties compared to previously used substitutes.
  • a variety of substitutes for pathologically changed, functionally important arteries and veins have been utilized in surgical treatment.
  • autologous material such as superficial veins from the lower extremities
  • non-autologous biological material such as chemically or physically treated blood vessels from other persons or from animals
  • synthetic materials such Dacron and Teflon ® tubes having varying structures depending on method of preparation
  • the intimal layer consists of a cell layer, whose functions are on one hand to prevent the formation of intravascular thrombi (anti-thrombogenic effect), and on the other hand to provide for exchange of metabolic products between the blood and smooth muscle ceils in the vascular wall.
  • a relatively thick and uniform layer of thrombotic material can be formed, building a scaffold for the proliferation of a endothelium coated muscle layer.
  • the resorbable material is arranged so that more or less continuous interspaces are formed within the resorbable material and/or between the resorbable and the at least partially non-resorbable materials. This can, for example, be achieved by spacing, preferably large, parts of the resorbable material from the non-resorbable material.
  • the resorbable layer or covering can be designed and applied in different ways.
  • the resorbable material may, for example, be an inner tubular member, which is inserted into and fixed to the outer tubular prosthesis element of non-resorbable material.
  • the inner tube may be formed of a coarse-to fine-meshed net, or may be a tube with perforated walls or walls having pores, etc.
  • the resorbable structure may e.g. further consist of a fine wire structure protruding from or fixed to the outer tubular member or be another correspondingly porous structure of a resorbable material, e.g. a spongy layer.
  • the attachment of the resorbable covering to the non-resorbable member may, of course, also take place before the prosthesis material is formed into a tube. It is also possible to cover the non-resorbable surface with the resorbable material by a method providing the necessary interspaces or growth zones as well as the necessary blood-cell pervious structure of the resorbable material. More detailed examples of the arrangement of the resorbable structure will be described below.
  • resorbable material To increase the thickness of the fibrin layer which in the initial stage after the implantation is to be retained by the resorbable material, two or possibly more, at least partially, mutually separated layers of resorbable material may be applied or, alternatively, a relatively thick layer with sufficient porosity or perforation may be used.
  • the resorbable net, tube etc. can be fixed to the non-resorbable prosthesis sleeve in different ways, e.g. with resorbable sutures or glue.
  • At least the inside of the outer non-resorbable member ought to be micro-porous, porous or provided with holes in order to promote the attachment of the reformed tissues.
  • Tubular prosthesis members of everything from a coarse-meshed net to a tube with fine pores may be used.
  • a suitable and well-functioning vascular prosthesis according to the invention can e.g. consist ol a per se conventional vascular prosthesis, on whose inside one or more nets of a resorbable material have been applied.
  • interspaces between non-resorbable and resorbable material in the vascular prosthesis can each have a greater or lesser extent, but the total area of these interspaces should preferably be so large that it approaches the size of the inner surface of the outer non-resorbable material layer, i.e. those portions or points where the resorbable material for fixing to the non-resorbable material contacts the latter should be as small as possible.
  • the distance between the material surfaces in these interspaces or growth zones should be at least about 10 ⁇ to permit penetration of the blood cells, but it should suitably not exceed about 5 to 10 mm even for large prostheses. Preferably said distance is about 0,5 to 3 mm, depending, of course, also on the size of the blood vessel to be replaced.
  • the resorbable material should be non-toxic without adverse tissue reaction, be resorbed at such a rate that a satisfactory reformation of tissue is permitted and not give rise to a fibrous scar tissue.
  • PGA polyglycolic acid
  • copolymers of glycolic acid and lactic acid and various lactide polymers may be mentioned.
  • Polyglycolic acid can essentially be considered as a product of polymerization of glycolic acid, that is hydroxyacetic acid, which in simplified form is shown by the equation:
  • n is such that the molecular weight is in the range from about 10.000 to about 500.000.
  • polyhydroxy acetic esters are described in e.g. U.S. Patent No. 3.463.158, which is incorporated by reference herein.
  • Copolymers of glycolic acid and lactic acid are described e.g. in U.S. Patent No. 3.982.543, which is incorporated by reference herein, the copolymer containing 15-85 mole percent glycolic acid and the remainder lactic acid and possibly small amounts of additional momomers.
  • Homopolymers and copolymers of lactic acid are described e.g. in U.S. Patent No. 3.636.956, which is incorporated by reference herein.
  • These polylactide compositions contain up to about 15 percent by weight of repeating units of the formula:
  • R is lower alkylene, preferably methylene or ethylene, m is 0 or 1
  • R' is hydrogen or lower alkyl
  • R" is hydrogen or alkyl of up to about 22 carbon atoms when m is 0, and hydrogen or lower alkyl when m is 1, and can be the same as R' or different.
  • Preferred are units derived from ⁇ -hydroxycarboxylic acids and particularly comonomer units derived from giycolide or DL-lactide.
  • Suitable comonomers are glycolide, ⁇ -propiolactone, tetramethylglycolide, ⁇ -butyrolactone, ⁇ -butyrolactone, pivalolactone, and intermolecular cyclic esters of ⁇ -hydroxybutyric acid, ⁇ -hydroxiisobutyric acid, ⁇ -hydroxyvaleric acid, ⁇ -hydroxyisovaleric acid, ⁇ -hydroxycapronic acid, ⁇ -hydroxy- ⁇ -ethylbutyric acid, ⁇ -hydroxyisocapronic acid, ⁇ -hydroxy-3-methylvaleric acid, ⁇ -hydroxyheptanoic acid, ⁇ - hydroxyoctanoic acid, ⁇ -hydroxydecanoic acid, ⁇ -hydroxymyristic acid, ⁇ -hydroxystearic acid and ⁇ -hydroxy lignoceric acid.
  • the polylactide composition may contain about 35 mole percent of repeating units derived therefrom.
  • suture wire such as suture wire, suture net, etc.
  • suture materials are also described in the literature.
  • Commercially available suture materials are e.g. Polyglactin 910 (VICRYI ® , Ethicon, Sommerville, New Jersey, USA), which is a copolymer containing 90% glycolic acid and 10% lactic acid and DEXON® (Davis & Geek, Pearl River, New York, USA) which consists of polyglycolic acid.
  • VIPYI ® Polyglactin 910
  • Ethicon Ethicon, Sommerville, New Jersey, USA
  • DEXON® Diavis & Geek, Pearl River, New York, USA
  • other materials can be used provided that they have the desired properties according to the above.
  • non-resorbable prosthesis part any conventional body-acceptable, non-resorbable material usually used for similar purposes may be used.
  • non-resorbable material usually used for similar purposes.
  • examples of such materials are polyethylene terephthalates, such as Dacron and Terylene, (e.g. micro-porous expanded) polytetrafluoroethylene (TEFLON ® , linear polyethene, isotactic polypropene, nylon, etc.
  • TEFLON ® micro-porous expanded polytetrafluoroethylene
  • This non-resorbable prosthesis part may as mentioned above be manufactured in various fabric forms (knitted, woven, possibly provided with outer and inner velour surfaces) or as a more or less porous tube.
  • the nonresorbable material may be combined with a resorbable material, e.g.
  • wires or fibres of a non-resorbable material coated with a resorbable material be made of wires or fibres of a non-resorbable material coated with a resorbable material, be woven with the interspersion of wires of resorbable material, have the inside coated by a resorbable material layer etc.
  • other materials having such properties that permit implantation may be used.
  • the prosthesis covering of resorbable material ought to be such that the absorption thereof in the organism takes at least 20 days, and preferably 40- 150 days.
  • Fig. 1 is a perspective view of an embodiment of a vascular prosthesis according to the invention.
  • Figs. 2 to 7 are schematic fragmentary sectional views of alternative embodiments of the invention.
  • the vascular prosthesis shown in Figure 1 comprises an outer tube 1 of a porous essentially non-resorbable material, and an inner covering or tube 2 of a resorbable material.
  • the inner tube 2 is in the figure formed of a net, which is attached to the outer tube 1 by means of a number of (not shown) sutures of a resorbable material.
  • the covering 2 contacts the outer tube 1 only at the fixing points, and the net portions therebetween remain spaced from the inner surface la of the tube 1 - as is schematically shown in Fig. 2 - and form the above mentioned growth zones, to which the blood cells after implantation can pass via the meshes of the net 2.
  • the mesh size of the net 2 is not critical as such but mesh sizes up to about 5 ⁇ 5 mm can conveniently be used.
  • a tubular element of a more or less (e.g. micro-porous) porous material e.g., both the outer tube 1 and the covering 2 may consist of nets, it also being possible to use woven or knitted materials.
  • the inner tube 2 can be a porous tube structure, while the outer tube 1 is a tubular net.
  • the fixing of the inner tube or covering 2 and the outer tube 1 can also be performed in another way than is shown above, e.g. by gluing with a suitable material.
  • the distance between the tube surface la and the covering 2 is suitably chosen such that it is about 0,5-3 mm.
  • the thickness of. the muscle cell/endothelium layer which is to be formed can be varied, e.g. by using several nets 2 separated by a suitable interspace as above.
  • the inner tube 2 is a porous tube
  • the thickness of the latter can be varied, it being understood, however, that the porosity according to the above should be sufficient for good penetration of the blood cells.
  • the thicknesses of the outer tube 1 and the covering layer 2 are suitably chosen such that the outer tube 1 corresponds to the outer layer of connective tissue (adventitia) and the layer 2 corresponds to the muscle cell and endothelium layer of the blood vessel or blood vessel part to be replaced by the vascular prosthesis. In the same way as in the case of nets it is possible to use several mutually separated layers of a porous material.
  • Figs. 2 to 7 schematically show some variations of the design and application of the inner wall construction 2 to the outer tube 1.
  • the resorbable material structure 2 is supposed to be a net (as in Fig. 1) or another porous flexible structure which remains spaced to the outer tube 1 between fixing points 3, so that interspaces 4 are formed between the respective portions of the inner wall 2 and the outer tube 1.
  • the inner wall 2 may, of course, also be a more rigid resorbable structure designed and fixed in the above manner.
  • the fixing means may e.g. be resorbable sutures or glue.
  • a tubular resorbable structure 2 having a smaller diameter than the inner diameter of the outer tube 1 is fixed to the latter through projections 5 of non-resorbable material extending from the outer tube 1, so that an interspace 4 is formed between the tubes.
  • Fig. 4 shows a similar arrangement, but here the projections or connecting elements 5 protrude from the resorbable structure 2.
  • the connecting parts 5 are fewer and thus more spaced apart.
  • the connecting elements or parts 5 may be arranged and designed in any suitable way. Thus, they may have a small wire-like dimension, and be uniformly or non-uniformly distributed along the material surfaces 1 and 2 in any suitable manner. They may, however, also have larger dimensions and can, for example, form partition walls or structures extending e.g. radially or circumferentially.
  • an inner tube or covering 2 is fixed to the outer tube 1 through a more porous or loose layer 6, e.g. a wire structure, of a resorbable or partially resorbable material.
  • a more porous or loose layer 6 e.g. a wire structure, of a resorbable or partially resorbable material.
  • the resorbable covering 2 is applied to the outer tube 1 without any proper spacing as above, and consists of a structure of a more porous nature, such as a fine wire-structure of loop or skein type, or of a highly porous or spongy material.
  • the layer 2 may further be e.g. a wire-structure in the form of a "nail or pin carpet” or the like having pins or wire protruding from a layer of a resorbable material applied to the non-resorbable material.
  • Figs. 1 to 7 are, as mentioned hereinbefore, only examples of various ways of providing the resorbable material, and further variations, such as various combinations of the above described examples are naturally possible within the invention.
  • an endothelium layer as well as an underlying cell layer of smooth muscle tissue is developed on the inside of the synthetic non-resorbable vascular prosthesis material.
  • the reformed layer on the inside of the synthetic material is developed in a short time through regeneration of normal constituents of the vascular wall from the edges of the animal's own vessels, while at the same time the resorbable material disappears.
  • the reformed endothelium presents properties characteristic of a normal endothelium.
  • the grafted vessel segment consists of an outer part of synthetic material, which gives a sufficient strength to the vessel, and of an inner part of body tissue having the structure of a normal vessel.
  • the vascular prosthesis according to the invention essentially functions as a normal blood vessel.
  • a vascular prosthesis was produced by applying a net of Polyglactin 910 (Vicryl ® , Ethicon, Sommerville, New Jersey, USA) on the inside of tube of expanded polytetrafluoroethyiene (Impra Inc., Phoenix, Arizona, USA) having a length of 10 cm and an inner diameter of 13 mm.
  • the net had a wire size of 140 + 20 ⁇ and a pore thickness of 400 ⁇ 400 ⁇ and was attached to the PTFE tube with polyglactin sutures.
  • the tube thus constructed was then sewn into pig thorax aorta as a replacement for an excised section.
  • a vascular prosthesis was produced as above, using as the outer tube a double velour knitted Dacron ® tube (Meadox Medicals, Oakland, New Jersey, USA) of the same length as above and with an inner diameter of 10 mm and as the inner tube a polyglactin net of the same type as in Example 1. The net was attached to the outer tube with polyglactin sutures. With this device the same experiment as in Example 1 was then performed. The result after six weeks implantation totally corresponded to the result of Example 1.
  • Example 1 A similar tube construction as in Example I was produced, a tube of Dacron fabric with a wire thickness of about 20 ⁇ and a mesh size of about 600 ⁇ 600 ⁇ being used as the outer tube, and the inner tube consisting of a polyglactin net of the same type as in Example 1. With this device the same experiment on pig as in Example 1 was then performed. The result after six weeks' implantation totally corresponded to the results in Example 1.
  • the invention is, of course, not restricted to the above specially described and shown embodiment, but many modifications and variations are possible within the scope of the subsequent claims. This applies especially to the resorbable and non-resorbable materials, the design of covering and outer tube, the dimensioning of the various components etc.

Abstract

Blood vessel prosthesis, comprising a tubular element (1) of an inert, completely or partially non-resorbable material having no adverse tissue reaction. To the inside of the tubular element (1) an interior wall construction of a resorbable material with no adverse tissue reaction is fixed, which wall construction (2) has such a structure that passage of blood cells, such as erythrocytes and thrombocytes, into or through the same is permitted.

Description

Blood vessel prosthesis
The present invention relates to a new type of blood vessel prosthesis for permanent or long-term implantation, which has clearly improved properties compared to previously used substitutes. A variety of substitutes for pathologically changed, functionally important arteries and veins have been utilized in surgical treatment. Thus, either autologous material (such as superficial veins from the lower extremities), non-autologous biological material (such as chemically or physically treated blood vessels from other persons or from animals) or synthetic materials (such Dacron and Teflon® tubes having varying structures depending on method of preparation) have been commonly used. As .substitutes for aorta and large branch arteries the synthetic materials have proved to give acceptable results. As substitutes for extremity arteries or arteries of a corresponding dimension the body's own veins have proved to give by far the best results. In many cases, however, the patient has no suitable vein material, and attempts have therefore been made to use a non-autologous material or a completely synthetic material. Such arterial reconstructions have, however, given inferior results. The factor above all contributing to the less favourable result is the absence of development of the specific inner coating characterizing a blood vessel, the intimal layer. The normal intimal layer consists of a cell layer, whose functions are on one hand to prevent the formation of intravascular thrombi (anti-thrombogenic effect), and on the other hand to provide for exchange of metabolic products between the blood and smooth muscle ceils in the vascular wall. On the inner aspect of the hitherto used vascular substitutes no endothelium is developed, but it is coated by a layer of fibrin and sometimes connective tissue. The resulting surface certainly appears to be smooth but lacks potent anti-thrombogenic properties. There is therefore a risk for formation of a thrombus, which may obstruct the inserted prosthesis completely with serious ischemic consequences for the patient. Essentially the same conditions will apply when replacing pathologically changed veins.
Previous attempts to attain an inner endothelial coating on synthetic vascular prostheses have been unsuccessful. This problem has now been solved through the present invention. It has been found that such an endothelial coating can be obtained by implantation of a vascular prosthesis composed of a completely or partially non-resorbable synthetic material, the inside of which is essentially covered by an inner wall construction of a resorbable material. To obtain the endothelium layer, the resorbable inner wall material should have such a porous structure that blood cells, such as erythrocytes and thrombocytes, may pass into or through it, so that it can serve as or define a growth zone or zones for the new tissue. Hereby a relatively thick and uniform layer of thrombotic material can be formed, building a scaffold for the proliferation of a endothelium coated muscle layer. Preferably the resorbable material is arranged so that more or less continuous interspaces are formed within the resorbable material and/or between the resorbable and the at least partially non-resorbable materials. This can, for example, be achieved by spacing, preferably large, parts of the resorbable material from the non-resorbable material.
The resorbable layer or covering can be designed and applied in different ways. Thus, the resorbable material may, for example, be an inner tubular member, which is inserted into and fixed to the outer tubular prosthesis element of non-resorbable material. The inner tube may be formed of a coarse-to fine-meshed net, or may be a tube with perforated walls or walls having pores, etc. The resorbable structure may e.g. further consist of a fine wire structure protruding from or fixed to the outer tubular member or be another correspondingly porous structure of a resorbable material, e.g. a spongy layer. The attachment of the resorbable covering to the non-resorbable member may, of course, also take place before the prosthesis material is formed into a tube. It is also possible to cover the non-resorbable surface with the resorbable material by a method providing the necessary interspaces or growth zones as well as the necessary blood-cell pervious structure of the resorbable material. More detailed examples of the arrangement of the resorbable structure will be described below.
To increase the thickness of the fibrin layer which in the initial stage after the implantation is to be retained by the resorbable material, two or possibly more, at least partially, mutually separated layers of resorbable material may be applied or, alternatively, a relatively thick layer with sufficient porosity or perforation may be used. The resorbable net, tube etc. can be fixed to the non-resorbable prosthesis sleeve in different ways, e.g. with resorbable sutures or glue.
At least the inside of the outer non-resorbable member ought to be micro-porous, porous or provided with holes in order to promote the attachment of the reformed tissues. Tubular prosthesis members of everything from a coarse-meshed net to a tube with fine pores may be used. A suitable and well-functioning vascular prosthesis according to the invention can e.g. consist ol a per se conventional vascular prosthesis, on whose inside one or more nets of a resorbable material have been applied.
The above mentioned interspaces between non-resorbable and resorbable material in the vascular prosthesis can each have a greater or lesser extent, but the total area of these interspaces should preferably be so large that it approaches the size of the inner surface of the outer non-resorbable material layer, i.e. those portions or points where the resorbable material for fixing to the non-resorbable material contacts the latter should be as small as possible. The distance between the material surfaces in these interspaces or growth zones should be at least about 10 μ to permit penetration of the blood cells, but it should suitably not exceed about 5 to 10 mm even for large prostheses. Preferably said distance is about 0,5 to 3 mm, depending, of course, also on the size of the blood vessel to be replaced.
The resorbable material should be non-toxic without adverse tissue reaction, be resorbed at such a rate that a satisfactory reformation of tissue is permitted and not give rise to a fibrous scar tissue. A number of such materials are previously known and are described in the literature. As examples polyglycolic acid (PGA), copolymers of glycolic acid and lactic acid, and various lactide polymers may be mentioned. Polyglycolic acid can essentially be considered as a product of polymerization of glycolic acid, that is hydroxyacetic acid, which in simplified form is shown by the equation:
Figure imgf000005_0001
Preferably n is such that the molecular weight is in the range from about 10.000 to about 500.000. Such polyhydroxy acetic esters are described in e.g. U.S. Patent No. 3.463.158, which is incorporated by reference herein. Copolymers of glycolic acid and lactic acid are described e.g. in U.S. Patent No. 3.982.543, which is incorporated by reference herein, the copolymer containing 15-85 mole percent glycolic acid and the remainder lactic acid and possibly small amounts of additional momomers. Homopolymers and copolymers of lactic acid are described e.g. in U.S. Patent No. 3.636.956, which is incorporated by reference herein. These polylactide compositions contain up to about 15 percent by weight of repeating units of the formula:
Figure imgf000005_0002
wherein R is lower alkylene, preferably methylene or ethylene, m is 0 or 1, R' is hydrogen or lower alkyl, R" is hydrogen or alkyl of up to about 22 carbon atoms when m is 0, and hydrogen or lower alkyl when m is 1, and can be the same as R' or different. Preferred are units derived from α-hydroxycarboxylic acids and particularly comonomer units derived from giycolide or DL-lactide. Examples of suitable comonomers are glycolide, β-propiolactone, tetramethylglycolide, β-butyrolactone, γ -butyrolactone, pivalolactone, and intermolecular cyclic esters of α-hydroxybutyric acid, α-hydroxiisobutyric acid, α-hydroxyvaleric acid, α-hydroxyisovaleric acid, α-hydroxycapronic acid, α-hydroxy-α-ethylbutyric acid, α-hydroxyisocapronic acid, α-hydroxy-3-methylvaleric acid, α-hydroxyheptanoic acid, α- hydroxyoctanoic acid, α-hydroxydecanoic acid, α-hydroxymyristic acid, α-hydroxystearic acid and α-hydroxy lignoceric acid. In the particular case with glycolide as comonomer the polylactide composition may contain about 35 mole percent of repeating units derived therefrom.
The manufacture of various surgical products, such as suture wire, suture net, etc. based upon the above. mentioned materials is also described in the literature. Examples of commercially available suture materials are e.g. Polyglactin 910 (VICRYI®, Ethicon, Sommerville, New Jersey, USA), which is a copolymer containing 90% glycolic acid and 10% lactic acid and DEXON® (Davis & Geek, Pearl River, New York, USA) which consists of polyglycolic acid. Of course, also other materials can be used provided that they have the desired properties according to the above.
As the material for the non-resorbable prosthesis part essentially any conventional body-acceptable, non-resorbable material usually used for similar purposes may be used. Examples of such materials are polyethylene terephthalates, such as Dacron and Terylene, (e.g. micro-porous expanded) polytetrafluoroethylene (TEFLON®, linear polyethene, isotactic polypropene, nylon, etc. This non-resorbable prosthesis part may as mentioned above be manufactured in various fabric forms (knitted, woven, possibly provided with outer and inner velour surfaces) or as a more or less porous tube. Optionally the nonresorbable material may be combined with a resorbable material, e.g. be made of wires or fibres of a non-resorbable material coated with a resorbable material, be woven with the interspersion of wires of resorbable material, have the inside coated by a resorbable material layer etc. Of course, also other materials having such properties that permit implantation may be used.
The prosthesis covering of resorbable material ought to be such that the absorption thereof in the organism takes at least 20 days, and preferably 40- 150 days.
The blood vessel prosthesis according to the invention will now be described in more detail by means of the following description of some specific non-limiting embodiments, refererence being made to the accompanying drawing, wherein
Fig. 1 is a perspective view of an embodiment of a vascular prosthesis according to the invention, and
Figs. 2 to 7 are schematic fragmentary sectional views of alternative embodiments of the invention. The vascular prosthesis shown in Figure 1 comprises an outer tube 1 of a porous essentially non-resorbable material, and an inner covering or tube 2 of a resorbable material. The inner tube 2 is in the figure formed of a net, which is attached to the outer tube 1 by means of a number of (not shown) sutures of a resorbable material. The covering 2 contacts the outer tube 1 only at the fixing points, and the net portions therebetween remain spaced from the inner surface la of the tube 1 - as is schematically shown in Fig. 2 - and form the above mentioned growth zones, to which the blood cells after implantation can pass via the meshes of the net 2. The mesh size of the net 2 is not critical as such but mesh sizes up to about 5 × 5 mm can conveniently be used. As mentioned above it is, for example, possible- to replace the net 2 with a tubular element of a more or less (e.g. micro-porous) porous material. Of course, both the outer tube 1 and the covering 2 may consist of nets, it also being possible to use woven or knitted materials. Further, the inner tube 2 can be a porous tube structure, while the outer tube 1 is a tubular net. The fixing of the inner tube or covering 2 and the outer tube 1 can also be performed in another way than is shown above, e.g. by gluing with a suitable material. The distance between the tube surface la and the covering 2 is suitably chosen such that it is about 0,5-3 mm.
The thickness of. the muscle cell/endothelium layer which is to be formed can be varied, e.g. by using several nets 2 separated by a suitable interspace as above. In the case that the inner tube 2 is a porous tube, the thickness of the latter can be varied, it being understood, however, that the porosity according to the above should be sufficient for good penetration of the blood cells. The thicknesses of the outer tube 1 and the covering layer 2 are suitably chosen such that the outer tube 1 corresponds to the outer layer of connective tissue (adventitia) and the layer 2 corresponds to the muscle cell and endothelium layer of the blood vessel or blood vessel part to be replaced by the vascular prosthesis. In the same way as in the case of nets it is possible to use several mutually separated layers of a porous material.
Figs. 2 to 7 schematically show some variations of the design and application of the inner wall construction 2 to the outer tube 1. Thus, in Fig. 2 the resorbable material structure 2 is supposed to be a net (as in Fig. 1) or another porous flexible structure which remains spaced to the outer tube 1 between fixing points 3, so that interspaces 4 are formed between the respective portions of the inner wall 2 and the outer tube 1. (The inner wall 2 may, of course, also be a more rigid resorbable structure designed and fixed in the above manner.) As mentioned above the fixing means may e.g. be resorbable sutures or glue.
In Fig. 3 a tubular resorbable structure 2 having a smaller diameter than the inner diameter of the outer tube 1 is fixed to the latter through projections 5 of non-resorbable material extending from the outer tube 1, so that an interspace 4 is formed between the tubes. Fig. 4 shows a similar arrangement, but here the projections or connecting elements 5 protrude from the resorbable structure 2.
In Fig. 5 the connecting parts 5 are fewer and thus more spaced apart. The connecting elements or parts 5 may be arranged and designed in any suitable way. Thus, they may have a small wire-like dimension, and be uniformly or non-uniformly distributed along the material surfaces 1 and 2 in any suitable manner. They may, however, also have larger dimensions and can, for example, form partition walls or structures extending e.g. radially or circumferentially. In Fig. 6 an inner tube or covering 2 is fixed to the outer tube 1 through a more porous or loose layer 6, e.g. a wire structure, of a resorbable or partially resorbable material. In Fig. 7, finally, the resorbable covering 2 is applied to the outer tube 1 without any proper spacing as above, and consists of a structure of a more porous nature, such as a fine wire-structure of loop or skein type, or of a highly porous or spongy material. The layer 2 may further be e.g. a wire-structure in the form of a "nail or pin carpet" or the like having pins or wire protruding from a layer of a resorbable material applied to the non-resorbable material.
The embodiments shown in Figs. 1 to 7 are, as mentioned hereinbefore, only examples of various ways of providing the resorbable material, and further variations, such as various combinations of the above described examples are naturally possible within the invention. In animal tests with the new vascular prosthesis according to the invention it has been found that an endothelium layer as well as an underlying cell layer of smooth muscle tissue is developed on the inside of the synthetic non-resorbable vascular prosthesis material. The reformed layer on the inside of the synthetic material is developed in a short time through regeneration of normal constituents of the vascular wall from the edges of the animal's own vessels, while at the same time the resorbable material disappears. The reformed endothelium presents properties characteristic of a normal endothelium. Thus, after the healing process is completed the grafted vessel segment consists of an outer part of synthetic material, which gives a sufficient strength to the vessel, and of an inner part of body tissue having the structure of a normal vessel. Thus, the vascular prosthesis according to the invention essentially functions as a normal blood vessel.
The invention is further illustrated by means of the subsequent examples of animal tests with a vascular prosthesis according to the invention (corresponding to the variant shown in Figs. 1 and 2), but it is, of course, in no way whatsoever restricted to the special prosthesis design used herein. Example 1
A vascular prosthesis was produced by applying a net of Polyglactin 910 (Vicryl®, Ethicon, Sommerville, New Jersey, USA) on the inside of tube of expanded polytetrafluoroethyiene (Impra Inc., Phoenix, Arizona, USA) having a length of 10 cm and an inner diameter of 13 mm. The net had a wire size of 140 + 20 μ and a pore thickness of 400 × 400 μ and was attached to the PTFE tube with polyglactin sutures. The tube thus constructed was then sewn into pig thorax aorta as a replacement for an excised section.
The implanted tube functioned quite satisfactorily, and six weeks after the operation the animal was slaughtered and the implanted portion taken care of for microscopic examination. The latter showed that the polyglactin net had been practically completely resorbed. At the place of the net a considerable layer of smooth muscle cells had grown in, and the inside of this layer was covered by endothelial cells. Example 2
A vascular prosthesis was produced as above, using as the outer tube a double velour knitted Dacron® tube (Meadox Medicals, Oakland, New Jersey, USA) of the same length as above and with an inner diameter of 10 mm and as the inner tube a polyglactin net of the same type as in Example 1. The net was attached to the outer tube with polyglactin sutures. With this device the same experiment as in Example 1 was then performed. The result after six weeks implantation totally corresponded to the result of Example 1. Example 3
A similar tube construction as in Example I was produced, a tube of Dacron fabric with a wire thickness of about 20 μ and a mesh size of about 600 × 600 μ being used as the outer tube, and the inner tube consisting of a polyglactin net of the same type as in Example 1. With this device the same experiment on pig as in Example 1 was then performed. The result after six weeks' implantation totally corresponded to the results in Example 1. The invention is, of course, not restricted to the above specially described and shown embodiment, but many modifications and variations are possible within the scope of the subsequent claims. This applies especially to the resorbable and non-resorbable materials, the design of covering and outer tube, the dimensioning of the various components etc.

Claims

1. A blood vessel prosthesis, comprising a tubular element of inert, at least partially non-resorbable material without adverse tissue reaction, characterized by a porous, essentially concentric inner wall construction (2) of a resorbable material without adverse tissue reaction fixed to said tubular element (1), which construction (2) has such a structure that passage of blood cells, such as erythrocytes and thrombocytes, into or through it is permitted.
2. A blood vessel prosthesis according to claim 1, characterized in that said inner wail construction (2) comprises parts spaced apart from the tubular element (1), thereby defining interspaces (4) between the tubular element (1) and said parts, into which the blood cells can pass.
3. A blood vessel prosthesis according to claim 1 or 2, characterized in that said inner wall construction (2) comprises one or more layers of a porous resorbable material.
4. A blood vessel prosthesis according to claim 1, 2 or 3, characterized in that said inner wall construction (2) comprises one or more nets of a resorbable material.
5. A blood vessel prosthesis according to any one of claims 1 to 4, characterized in that the tubular element (1) is micro-porous or porous.
6. A blood vessel prosthesis according to any one of claims 1 to 5, characterized in that the resorbable material comprises poiyglycolic acid, copolymeres of glycolic acid and lactic acid or lactide poiymeres or copolymeres.
7. A blood vessel prosthesis according to any one of claims 1 , to 6, characterized in that the material of the tubular element (1) is chosen from polyethylene terephthalates, polytetrafluoroethene, poiyethene and polypropene.
8. A blood vessel prosthesis according to any one of claims 5 to 7, characterized In that the tubular element (1) is woven or knitted.
9. A blood vessel prosthesis according to any one of claims 2 to 8, characterized in that said interspaces (4) between the interior wall (2) and the tubular element (1) amounts to about 10 μ - 5 mm.
10. A method of replacing blood vessels or parts thereof, characterized by implanting a blood vessel prosthesis according to any one of claims 1 to 9.
PCT/SE1980/000161 1979-06-06 1980-06-04 Blood vessel prosthesis WO1980002641A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
DE803047573T DE3047573T1 (en) 1979-06-06 1980-06-04 BLOOD VESSEL PROSTHESIS
AU59897/80A AU539875B2 (en) 1979-06-06 1980-06-04 Blood vessel prosthesis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE7904938A SE424401B (en) 1979-06-06 1979-06-06 BLODKERLSPROTES
SE7904938 1979-06-06

Publications (1)

Publication Number Publication Date
WO1980002641A1 true WO1980002641A1 (en) 1980-12-11

Family

ID=20338221

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE1980/000161 WO1980002641A1 (en) 1979-06-06 1980-06-04 Blood vessel prosthesis

Country Status (11)

Country Link
JP (1) JPS6318508B2 (en)
AU (1) AU539875B2 (en)
BE (1) BE883646A (en)
CA (1) CA1166802A (en)
CH (1) CH645532A5 (en)
DE (1) DE3047573T1 (en)
FR (1) FR2458274A1 (en)
GB (1) GB2063685B (en)
NL (1) NL8020201A (en)
SE (1) SE424401B (en)
WO (1) WO1980002641A1 (en)

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0117072A1 (en) * 1983-01-25 1984-08-29 J. & P. Coats, Limited Vascular prosthesis
FR2541888A1 (en) * 1983-03-04 1984-09-07 Sgro Jean Claude Partially resorbable vascular prosthesis
US4483339A (en) * 1982-01-29 1984-11-20 Rolando Gillis Vascular surgery roll
EP0128741A1 (en) * 1983-06-07 1984-12-19 Toray Industries, Inc. Artificial vascular graft
US4670286A (en) * 1983-09-20 1987-06-02 Allied Corporation Method of forming prosthetic devices
US4687482A (en) * 1984-04-27 1987-08-18 Scripps Clinic And Research Foundation Vascular prosthesis
EP0334024A2 (en) * 1988-03-22 1989-09-27 American Cyanamid Company Prosthetic tubular article
US4942875A (en) * 1986-03-03 1990-07-24 American Cyanamid Company Surgical repair device having absorbable and nonabsorbable components
EP0382158A1 (en) * 1989-02-07 1990-08-16 Terumo Kabushiki Kaisha Prosthesis for living organ
EP0385925A1 (en) * 1989-02-28 1990-09-05 GebràœDer Sulzer Aktiengesellschaft Plaited vascular prosthesis
EP0686379A2 (en) 1994-06-08 1995-12-13 Cardiovascular Concepts, Inc. Apparatus for endoluminal graft placement
US5632776A (en) * 1990-11-22 1997-05-27 Toray Industries, Inc. Implantation materials
US5976192A (en) * 1995-06-07 1999-11-02 Baxter International Inc. Method of forming an externally supported tape reinforced vascular graft
US5980564A (en) * 1997-08-01 1999-11-09 Schneider (Usa) Inc. Bioabsorbable implantable endoprosthesis with reservoir
US6156064A (en) * 1998-08-14 2000-12-05 Schneider (Usa) Inc Stent-graft-membrane and method of making the same
US6174330B1 (en) 1997-08-01 2001-01-16 Schneider (Usa) Inc Bioabsorbable marker having radiopaque constituents
US6206883B1 (en) 1999-03-05 2001-03-27 Stryker Technologies Corporation Bioabsorbable materials and medical devices made therefrom
US6245103B1 (en) 1997-08-01 2001-06-12 Schneider (Usa) Inc Bioabsorbable self-expanding stent
US6251135B1 (en) 1997-08-01 2001-06-26 Schneider (Usa) Inc Radiopaque marker system and method of use
WO2003051420A1 (en) * 2001-12-14 2003-06-26 Yasuharu Noishiki Lumen formation-inducible material and instrument to be inserted into the body
US6747121B2 (en) 2001-09-05 2004-06-08 Synthes (Usa) Poly(L-lactide-co-glycolide) copolymers, methods for making and using same, and devices containing same
US7699887B2 (en) 1997-12-18 2010-04-20 Boston Scientific Scimed, Inc. Stent-graft with bioabsorbable structural support

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE446372B (en) * 1983-02-03 1986-09-08 Medinvent Sa BLOODKERL PROTES FOR USE AS SHUNT BETWEEN BLOODKERL
US4716900A (en) * 1986-05-09 1988-01-05 Pfizer Hospital Products Group, Inc. Intraintestinal bypass graft
ES2056978T3 (en) * 1988-03-22 1994-10-16 American Cyanamid Co PROSTHETIC ARTICLE.
JP2005034239A (en) * 2003-07-16 2005-02-10 Gunze Ltd Base material for artificial blood vessel

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2017330A1 (en) * 1970-04-10 1971-12-09 BIO-CAL Instrument GmbH, 8032 Gräfelfing Blood vessel connector - for artificial kidneys or lungs
US4086665A (en) * 1976-12-16 1978-05-02 Thermo Electron Corporation Artificial blood conduit

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1491218C3 (en) * 1963-06-15 1973-01-04 Spofa Sdruzheni Podniku Pro Zdravotnickou Vyrobu, Prag Blood vessel prosthesis and method for making the same
US3463158A (en) * 1963-10-31 1969-08-26 American Cyanamid Co Polyglycolic acid prosthetic devices
BE758156R (en) * 1970-05-13 1971-04-28 Ethicon Inc ABSORBABLE SUTURE ELEMENT AND ITS
US3688317A (en) * 1970-08-25 1972-09-05 Sutures Inc Vascular prosthetic
US3982543A (en) * 1973-04-24 1976-09-28 American Cyanamid Company Reducing capillarity of polyglycolic acid sutures
US3914802A (en) * 1974-05-23 1975-10-28 Ebert Michael Non-thrombogenic prosthetic material
JPS515897A (en) * 1974-07-02 1976-01-19 Hiroshi Matsumoto Jinkoketsukan oyobi sonoseizohoho
DE2654658A1 (en) * 1975-12-02 1977-06-08 Rhone Poulenc Ind IMPLANTABLE SURGICAL LEAD
US4130904A (en) * 1977-06-06 1978-12-26 Thermo Electron Corporation Prosthetic blood conduit

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2017330A1 (en) * 1970-04-10 1971-12-09 BIO-CAL Instrument GmbH, 8032 Gräfelfing Blood vessel connector - for artificial kidneys or lungs
US4086665A (en) * 1976-12-16 1978-05-02 Thermo Electron Corporation Artificial blood conduit

Cited By (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4483339A (en) * 1982-01-29 1984-11-20 Rolando Gillis Vascular surgery roll
EP0117072A1 (en) * 1983-01-25 1984-08-29 J. & P. Coats, Limited Vascular prosthesis
FR2541888A1 (en) * 1983-03-04 1984-09-07 Sgro Jean Claude Partially resorbable vascular prosthesis
EP0128741A1 (en) * 1983-06-07 1984-12-19 Toray Industries, Inc. Artificial vascular graft
US4670286A (en) * 1983-09-20 1987-06-02 Allied Corporation Method of forming prosthetic devices
US4687482A (en) * 1984-04-27 1987-08-18 Scripps Clinic And Research Foundation Vascular prosthesis
US4942875A (en) * 1986-03-03 1990-07-24 American Cyanamid Company Surgical repair device having absorbable and nonabsorbable components
EP0334024A2 (en) * 1988-03-22 1989-09-27 American Cyanamid Company Prosthetic tubular article
EP0334024A3 (en) * 1988-03-22 1989-12-27 American Cyanamid Company Prosthetic tubular article
EP0382158A1 (en) * 1989-02-07 1990-08-16 Terumo Kabushiki Kaisha Prosthesis for living organ
EP0385925A1 (en) * 1989-02-28 1990-09-05 GebràœDer Sulzer Aktiengesellschaft Plaited vascular prosthesis
CH677186A5 (en) * 1989-02-28 1991-04-30 Sulzer Ag
US5632776A (en) * 1990-11-22 1997-05-27 Toray Industries, Inc. Implantation materials
EP0686379A2 (en) 1994-06-08 1995-12-13 Cardiovascular Concepts, Inc. Apparatus for endoluminal graft placement
US5976192A (en) * 1995-06-07 1999-11-02 Baxter International Inc. Method of forming an externally supported tape reinforced vascular graft
US5980564A (en) * 1997-08-01 1999-11-09 Schneider (Usa) Inc. Bioabsorbable implantable endoprosthesis with reservoir
US7553325B2 (en) 1997-08-01 2009-06-30 Boston Scientific Scimed, Inc. Bioabsorbable marker having radiopaque constituents
US6174330B1 (en) 1997-08-01 2001-01-16 Schneider (Usa) Inc Bioabsorbable marker having radiopaque constituents
US6245103B1 (en) 1997-08-01 2001-06-12 Schneider (Usa) Inc Bioabsorbable self-expanding stent
US6251135B1 (en) 1997-08-01 2001-06-26 Schneider (Usa) Inc Radiopaque marker system and method of use
US6340367B1 (en) 1997-08-01 2002-01-22 Boston Scientific Scimed, Inc. Radiopaque markers and methods of using the same
US9833343B2 (en) 1997-12-18 2017-12-05 Boston Scientific Scimed, Inc. Stent-graft with bioabsorbable structural support
US7699887B2 (en) 1997-12-18 2010-04-20 Boston Scientific Scimed, Inc. Stent-graft with bioabsorbable structural support
US6156064A (en) * 1998-08-14 2000-12-05 Schneider (Usa) Inc Stent-graft-membrane and method of making the same
US6709455B1 (en) 1998-08-14 2004-03-23 Boston Scientific Scimed, Inc. Stent-graft-membrane and method of making the same
US6716957B2 (en) 1999-03-05 2004-04-06 Stryker Technologies Corporation Bioabsorbable materials and medical devices made therefrom
US6206883B1 (en) 1999-03-05 2001-03-27 Stryker Technologies Corporation Bioabsorbable materials and medical devices made therefrom
US6747121B2 (en) 2001-09-05 2004-06-08 Synthes (Usa) Poly(L-lactide-co-glycolide) copolymers, methods for making and using same, and devices containing same
EP1459772A1 (en) * 2001-12-14 2004-09-22 Yasuharu Noishiki Fistula formation-inducing material and body insertion device
WO2003051420A1 (en) * 2001-12-14 2003-06-26 Yasuharu Noishiki Lumen formation-inducible material and instrument to be inserted into the body
EP1459772A4 (en) * 2001-12-14 2010-10-06 Yasuharu Noishiki Fistula formation-inducing material and body insertion device
US7833148B2 (en) 2001-12-14 2010-11-16 Yasuharu Noishiki Lumen formation-inducible material and instrument to be inserted into the body

Also Published As

Publication number Publication date
DE3047573T1 (en) 1982-02-18
NL8020201A (en) 1981-03-31
GB2063685A (en) 1981-06-10
SE424401B (en) 1982-07-19
GB2063685B (en) 1983-05-18
AU539875B2 (en) 1984-10-18
SE7904938L (en) 1980-12-07
JPS56500760A (en) 1981-06-11
BE883646A (en) 1980-10-01
AU5989780A (en) 1980-12-22
CH645532A5 (en) 1984-10-15
DE3047573C2 (en) 1990-06-28
CA1166802A (en) 1984-05-08
FR2458274A1 (en) 1981-01-02
JPS6318508B2 (en) 1988-04-19
FR2458274B1 (en) 1983-12-09

Similar Documents

Publication Publication Date Title
US4416028A (en) Blood vessel prosthesis
WO1980002641A1 (en) Blood vessel prosthesis
US4670286A (en) Method of forming prosthetic devices
US4594407A (en) Prosthetic devices derived from krebs-cycle dicarboxylic acids and diols
EP0349505B1 (en) A novel surgical material
JP4480928B2 (en) Reinforced tissue graft and methods of making and using the same
US7914808B2 (en) Hybrid biologic/synthetic porous extracellular matrix scaffolds
US4712553A (en) Sutures having a porous surface
US5358475A (en) High molecular weight bioresorbable polymers and implantable devices thereof
Hoppen et al. Two-ply biodegradable nerve guide: basic aspects of design, construction and biological performance
AU2002316694A1 (en) Hybrid biologic/synthetic porous extracellular matrix scaffolds
EP1545390A1 (en) Three dimensional implant
Ikada Bioabsorbable fibers for medical use
EP0326583B1 (en) Implantable devices having hydrophobic component
Ashammakhi Neomembranes: A concept review with special reference to self‐reinforced polyglycolide membranes
US5641505A (en) Porous flexible sheet for tissue separation
US20220354632A1 (en) Tissue engineered vascular grafts
KR0165642B1 (en) Biodegradable membranes for implanting and process for the preparation thereof
EP3285684A1 (en) Absorbable implants for plastic surgery
CN117065096B (en) Rapid preparation method and application of biological film
Shalaby et al. Synthetic vascular constructs
Van der Lei et al. Patency and healing of microvascular prostheses: a review of 10 years of experimental work in Groningen

Legal Events

Date Code Title Description
AK Designated states

Designated state(s): AU CH DE GB JP NL US

RET De translation (de og part 6b)

Ref document number: 3047573

Country of ref document: DE

Date of ref document: 19820218

WWE Wipo information: entry into national phase

Ref document number: 3047573

Country of ref document: DE